Frequency of patients in flare at each time point over 3 months

Slides:

Advertisements

Similar presentations

Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from baseline to 12 months follow-up in patients.

Advertisements

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The landscape of cytokine-producing CD4 T cell populations in the peripheral blood (PB) and in the joints. Venn diagrams show the frequency of overlapping.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Three different reconstructions after one single mDixon sequence of

Resolution of tophi after exposure to pegloticase.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Imaging of patient 1. Imaging of patient 1. (A) Muscle MRI of both legs performed at the age of 5 years: coronal gadolinium-enhanced T1-weighted sequence.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as domains for the annual systemic assessment of.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Employment of patients with AS compared with controls, by BASDAI

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Subject disposition through week 156 of treatment

Mean (SE) maximum urinary uric acid excretion rate (mg/hour) following verinurad doses in combination with febuxostat 40 or 80 mg vs febuxostat 40 or 80 mg.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed to Ehlers-Danlos Syndromes (EDS)

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Classification tree with the selected characteristics.

Follow-up and cause of anti-TNF-α discontinuation in 15 patients with rhupus. anti-TNF-α, antitumour necrosis factor alpha; ESR, erythrocyte sediment rate;

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

Joint pain location and severity.

Kaplan-Meier estimate of drug continuation until discontinuation for tocilizumab, canakinumab, anakinra and etanercept, as a first biological agent for.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Depiction of bone marrow oedema using different techniques

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.

NRDC and TNF-α increase in synovial fluid from patients with RA

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

Frequency of patients in flare at each time point over 3 months Frequency of patients in flare at each time point over 3 months. x-Axis, questionnaire number since the beginning of the study; y-axis, proportion of patients in flare (%). Frequency of patients in flare at each time point over 3 months. x-Axis, questionnaire number since the beginning of the study; y-axis, proportion of patients in flare (%). Charlotte Jacquemin et al. RMD Open 2017;3:e000434 Copyright © BMJ Publishing Group & EULAR. All rights reserved.